Get the Stockscreener App
4.58
10.90%
0.45
After Hours:
4.51
-0.07
-1.53%
Taysha Gene Therapies Inc stock is traded at $4.58, with a volume of 3.14M.
It is up +10.90% in the last 24 hours and down -1.93% over the past month.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
See More
Previous Close:
$4.13
Open:
$4.22
24h Volume:
3.14M
Relative Volume:
1.15
Market Cap:
$1.32B
Revenue:
$9.77M
Net Income/Loss:
$-109.00M
P/E Ratio:
-12.71
EPS:
-0.3604
Net Cash Flow:
$-93.83M
1W Performance:
+2.92%
1M Performance:
-1.93%
6M Performance:
+49.67%
1Y Performance:
+158.76%
1-Day Range:
$4.20
$4.59
1-Week Range:
$4.075
$4.66
52-Week Range:
$1.05
$6.02
Taysha Gene Therapies Inc Stock (TSHA) Company Profile
Name
Taysha Gene Therapies Inc
Sector
Industry
Phone
(214) 612-0000
Address
3000 PEGASUS PARK DRIVE, DALLAS
Compare TSHA vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TSHA
Taysha Gene Therapies Inc
|
4.58 | 1.19B | 9.77M | -109.00M | -93.83M | -0.3604 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-21-25 | Initiated | Raymond James | Strong Buy |
| Jul-11-25 | Initiated | BofA Securities | Buy |
| Jun-27-24 | Initiated | BMO Capital Markets | Outperform |
| Apr-09-24 | Initiated | Piper Sandler | Overweight |
| Feb-01-23 | Downgrade | Jefferies | Buy → Hold |
| Jan-27-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-09-22 | Downgrade | Goldman | Buy → Neutral |
| Mar-09-22 | Initiated | Robert W. Baird | Outperform |
| Mar-01-22 | Initiated | Wells Fargo | Overweight |
| Feb-18-22 | Initiated | SMBC Nikko | Outperform |
| Dec-16-21 | Initiated | Guggenheim | Buy |
| Jul-16-21 | Initiated | Needham | Buy |
| Jun-24-21 | Initiated | Truist | Buy |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| Jun-09-21 | Initiated | Wedbush | Outperform |
| Jun-08-21 | Initiated | JMP Securities | Mkt Outperform |
| May-19-21 | Initiated | Cantor Fitzgerald | Overweight |
| May-11-21 | Resumed | Jefferies | Buy |
| Feb-24-21 | Initiated | William Blair | Outperform |
| Jan-05-21 | Initiated | Oppenheimer | Outperform |
| Oct-19-20 | Initiated | Chardan Capital Markets | Buy |
| Oct-19-20 | Initiated | Goldman | Buy |
| Oct-19-20 | Initiated | Jefferies | Buy |
| Oct-19-20 | Initiated | Morgan Stanley | Overweight |
View All
Taysha Gene Therapies Inc Stock (TSHA) Latest News
Panic Selling: Whats the fair value of Taysha Gene Therapies Inc stockCEO Change & Technical Entry and Exit Alerts - baoquankhu1.vn
Levels Update: Whats the fair value of Taysha Gene Therapies Inc stock2026 Winners & Losers & AI Powered Trade Plan Recommendations - baoquankhu1.vn
Taysha Gene Therapies (NASDAQ:TSHA) Trading Up 8.5%Should You Buy? - MarketBeat
Cantor Fitzgerald reiterates Overweight on Taysha Gene Therapies stock By Investing.com - Investing.com Canada
Cantor Fitzgerald Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $19 - Moomoo
Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 6.9%Time to Sell? - MarketBeat
Taysha outlines 2026 BLA submission path for TSHA-102 as pivotal trial enrollment advances - MSN
How FDA Breakthrough Status For TSHA-102 At Taysha Gene Therapies (TSHA) Has Changed Its Investment Story - Yahoo Finance
Taysha Gene Therapies Receives 'Moderate Buy' Rating from Analysts - National Today
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Taysha Gene Therapies Advances Rett Program As Valuation Draws Investor Focus - Sahm
Taysha Gene Therapies (NASDAQ:TSHA) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Chardan Capital Maintains Taysha Gene Therapies (TSHA) Buy Recommendation - MSN
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q4 2025 Earnings Call Transcript - Insider Monkey
Taysha Gene Therapies (NASDAQ:TSHA) Price Target Raised to $12.00 at Needham & Company LLC - MarketBeat
Decoding Taysha Gene Therapies Inc (TSHA): A Strategic SWOT Insi - GuruFocus
Taysha Gene Therapies Q4 Loss Of US$27.9m Tests Bullish TSHA 102 Narrative - simplywall.st
Taysha Gene Therapies Signals Momentum in Earnings Call - TipRanks
Taysha Gene Therapies (TSHA) Advances Rett Syndrome Treatment - GuruFocus
Jefferies raises Taysha Gene Therapies price target on trial progress By Investing.com - Investing.com Canada
Key facts: Taysha $109M loss; Q4 rev +171%; $320M cash; TSHA-102 safe, Q2'26 - TradingView
TSHA: Analyst Chardan Capital Maintains Buy Rating with $12 PT | - GuruFocus
Chardan Capital Reaffirms "Buy" Rating for Taysha Gene Therapies (NASDAQ:TSHA) - MarketBeat
Raymond James reiterates Strong Buy on Taysha Gene Therapies stock By Investing.com - Investing.com Australia
Taysha Gene Therapies Inc (TSHA) Q4 2025 Earnings Call Highlight - GuruFocus
Taysha Gene Therapies Q4 2025 Earnings Call Transcript - MarketBeat
Taysha Gene Therapies, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Taysha Gene Therapies’ Q4 Earnings Call: FDA Timeline, European Strategy Claims Don’t Match Prior Statements - Bitget
Taysha (TSHA) Reports Strong Q4 Revenue and Promising Progress i - GuruFocus
Taysha Gene Therapies Q4 Earnings Call Highlights - MarketBeat
Taysha Gene Therapies 2026 Conference Call: TSHA-102 Development & Regulatory PlansNews and Statistics - IndexBox
Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update - Investing News Network
TSHA: TSHA-102 advanced toward registration with strong trial data, FDA alignment, and solid cash runway - TradingView
Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Up After Better-Than-Expected Earnings - MarketBeat
Taysha Gene Therapies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Taysha (TSHA) Fourth Quarter 2025 Earnings Conference Call Transcript - Bitget
Taysha (TSHA) Q4 2025 Earnings Call Transcript - AOL.com
Earnings call transcript: Taysha Gene Therapies Q4 2025 sees widened loss - Investing.com India
Earnings call transcript: Taysha Gene Therapies Q4 2025 sees widened loss By Investing.com - Investing.com South Africa
Taysha Gene Therapies (NASDAQ:TSHA) Releases Earnings Results, Beats Expectations By $0.03 EPS - MarketBeat
Valuation Update: How correlated is Taysha Gene Therapies Inc to the S P5002026 Price Momentum & Daily Oversold Bounce Ideas - baoquankhu1.vn
Taysha Gene Therapies, Inc. Appoints Brad Martin as Senior Vice President, Market Access and Value - marketscreener.com
Taysha (TSHA) Reports Strong Q4 Revenue and Promising Progress in Trials - GuruFocus
Taysha Gene Therapies 10-K: $9.8M Revenue, $(0.34) EPS - TradingView
Rett gene therapy advances at Taysha Gene Therapies (TSHA) - Stock Titan
Taysha Gene Therapies reports full-year 2025 earnings and issues corporate update - Traders Union
Earnings Flash (TSHA) Taysha Gene Therapies Posts 2025 Revenue $9.8M, vs. FactSet Est of $5.9M - marketscreener.com
Earnings Flash (TSHA) Taysha Gene Therapies Posts 2025 Net Loss $0.34 a Share, vs. FactSet Est of $0.37 Loss - marketscreener.com
Taysha Gene Therap Reports 2025 Full-Year Results — $9.8M Revenue, $109.0M Net Loss - TradingView
Taysha Gene Therapies (TSHA) deepens 2025 loss but advances Rett trial - Stock Titan
TSHA: TSHA-102 trials progressed with strong safety, regulatory alignment, and robust cash position - TradingView
Taysha Gene Therapies Inc Stock (TSHA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):